NewsRoom Articles - BioMedWire (BMW)

WednesdayJul 08, 2026 10:30 am

VERAXA Biotech AG (NASDAQ: VRXA) Advances Lead BiTAC(R) T-Cell Engager Program with Cell Line Development Partnership

The company has initiated cell line development for its lead BiTAC(R) T-cell engager program, selecting ATUM to support manufacturing development as the candidate advances toward IND/CTA-enabling studies. ATUM will apply its Leap-In Transposase(R) technology to generate stable clonal cell lines for VERAXA's lead therapeutic candidate. The collaboration represents an important development milestone, supporting manufacturing, analytical development and nonclinical studies required before clinical testing. VERAXA's BiTAC(R) platform is designed to improve the selectivity of T-cell engagers, potentially reducing toxicity associated with conventional approaches. The company recently expanded its research facilities in Heidelberg, Germany, increasing laboratory capacity as multiple oncology programs move…

WednesdayJul 08, 2026 9:45 am

Earth Science Tech Inc. (ETST) Is Building on Unique Competitive Advantages to Deliver Steady Growth

Earth Science Tech acquires, operates, optimizes, and manages autonomous revenue-generating divisions across pharmaceuticals, telemedicine, retail, and real estate development This approach has created a “conglomerate” business model that separates ETST from other healthcare companies and enables the company to capture the profit margins at every step that other companies are forced to outsource ETST’s competitive advantages include its end-to-end vertical integration that covers all aspects of patient care (consultation, pharmacies, and fulfillment) as well as the provision of B2B tech and real estate This vertical integration has resulted in direct revenue growth while continually building the company’s product pipeline Earth…

TuesdayJul 07, 2026 10:00 am

Supreme Court Ruling Could Worsen the US Healthcare Crisis

There is general agreement that the healthcare system in the U.S. is in crisis, and a recent ruling issued by the Supreme Court could worsen the situation. This particular ruling allowed the federal government to end the TPS (temporary protected status) of noncitizens from particular countries, in this case Syria and Haiti. Under the TPS law that was passed back in 1990, the government, through Homeland Security, could grant temporary protected status to noncitizens from listed countries if those countries were deemed to be unsafe for their citizens in the U.S. to go back. The grounds for granting this status…

TuesdayJul 07, 2026 9:45 am

The $15 Billion Knee OA Spending Gap: Why Gelrin C Is the Smartest Investment in Cartilage Economics

Knee osteoarthritis costs the U.S. healthcare system billions of dollars annually, creating growing demand for treatment options that can address cartilage damage before it progresses to more costly joint degeneration. Unlike complex cell-based therapies that often require multiple procedures and specialized laboratory processing, Gelrin C from Regentis is a cell-free, off-the-shelf hydrogel designed to fit within existing surgical workflows. With approximately 470,000 cartilage repair procedures performed annually in the U.S., Regentis is targeting a multi-billion-dollar market where providers, payers and patients are seeking more practical regenerative solutions. What begins as a localized cartilage defect can ultimately evolve into a significant…

MondayJul 06, 2026 10:00 am

UCS Unveils Tool to Track Attacks Against Science in the US

The Union of Concerned Scientists (UCS) has unveiled an interactive tool geared toward documenting and highlighting the different ways through which science has come under attack from the time Trump took office for the second time. The tool also documents possible violations of draft legislation before Congress, called the Scientific Integrity Act. The tool, dubbed Attacks on Science Tracker, so far has a total of 576 attacks against science and 188 incidents that are categorized as possible violations of the Scientific Integrity Act. These cases span from January 2025 up to June 29, 2026. The developers of the tool aimed to bring to the public’s attention the different ways through which political and elected…

ThursdayJul 02, 2026 10:00 am

Comprehensive Review Shows Gut Microbiome Influences Immunotherapy Efficacy

Scientists have for long been concerned about why some people with liver cancer respond when given immunotherapy but others don’t. A recent comprehensive review provides key insights linking how patients respond to these treatments to the status of their gut microbiome. The review, published in the journal Cancer Biology and Medicine, was conducted by a team based at the Chinese University of Hong Kong. The scientists compiled recent scientific data detailing how the microbial composition of the gut impacts how different patients respond when they are given immune checkpoint blockade therapies against hepatocellular carcinoma, the most common type of liver cancer. They found that anti-tumor immune activity is modulated or influenced…

WednesdayJul 01, 2026 10:40 am

Why VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals

Deal activity remains strong in antibody-drug conjugates (ADCs) and T-cell engager (TCE) therapeutics, with pharmaceutical companies continuing to commit substantial capital to preclinical and early-stage innovation. The Jazz Pharmaceuticals–AbCellera collaboration illustrates how differentiated antibody technologies can command significant financial commitments before entering clinical development. VERAXA Biotech AG is positioning its technology platform across both ADCs and T-cell engagers, two therapeutic modalities that continue to attract strategic partnerships and acquisitions. Platform technologies and individual drug candidates both represent potential avenues for future partnering, licensing, and collaboration agreements. Recent transactions across the sector demonstrate that pharmaceutical companies are actively seeking access to…

WednesdayJul 01, 2026 10:30 am

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Delivers First Edge AI Intoxication Detection Kiosk Prototypes

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. MindBio kiosks use artificial intelligence and voice analysis to detect potential intoxication and fatigue in workplace environments. The company is targeting industries such as mining, aviation, construction, transportation, and law enforcement, where safety-sensitive operations require large-scale screening. MindBio’s AI models have been trained on more than 50 million data points and analyze over 140 acoustic markers associated with impairment. Prototype kiosks are entering testing, validation, and data-analysis phases, before broader commercial deployment. The company is positioning this important new technology as a faster and less invasive…

WednesdayJul 01, 2026 9:45 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive Podcast

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma executive co-chairman and co-founder Anthony Durkacz appeared as a guest on the BioMedWire Podcast. Durkacz outlined the company’s strategy for advancing Lucid-MS, the company’s lead drug candidate for multiple sclerosis. The Quantum BioPharma exec also provided an update on unbuzzd, the company’s innovative, clinically validated alcohol metabolism accelerator designed to help sober people up faster. Executive thought leadership has become an increasingly important component of corporate communications, particularly in highly specialized industries such as biotechnology. Through podcasts, interviews and other educational forums, company leaders…

TuesdayJun 30, 2026 10:00 am

Currently Approved Drug Could Boost Immunotherapy Against Liver Cancer

Researchers at University of Washington have discovered that a drug that is currently approved by the FDA could help in boosting the efficacy of immunotherapy against a rare type of liver cancer that has previously been unresponsive to checkpoint inhibitors. The preclinical study, whose findings appeared in the Gastroenterology journal, found that fibrolamellar carcinoma, an aggressive type of liver cancer, alters normal liver cells and causes them to produce the fibrous tissue that is characteristic of this type of cancer. T-cells that are meant to fight the cancer are then rechanneled into these fibrous bands and trapped there. As a result of this entrapment, the body’s immune…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

VERAXA Biotech AG (NASDAQ: VRXA) Advances Lead BiTAC(R) T-Cell Engager Program with Cell Line Development Partnership

Earth Science Tech Inc. (ETST) Is Building on Unique Competitive Advantages to Deliver Steady Growth

Supreme Court Ruling Could Worsen the US Healthcare Crisis

The $15 Billion Knee OA Spending Gap: Why Gelrin C Is the Smartest Investment in Cartilage Economics

UCS Unveils Tool to Track Attacks Against Science in the US

Comprehensive Review Shows Gut Microbiome Influences Immunotherapy Efficacy

Why VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Delivers First Edge AI Intoxication Detection Kiosk Prototypes

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive Podcast

Currently Approved Drug Could Boost Immunotherapy Against Liver Cancer

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search